Clinical Trial Detail

NCT ID NCT02961374
Title Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications
Therapies

Erlotinib

Age Groups: adult senior

Additional content available in CKB BOOST